<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02230319</url>
  </required_header>
  <id_info>
    <org_study_id>2014.1</org_study_id>
    <nct_id>NCT02230319</nct_id>
  </id_info>
  <brief_title>Prevention of Paclitaxel Neuropathy With Cryotherapy</brief_title>
  <official_title>Prevention of Paclitaxel Neuropathy With Cryotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Oncology &amp; Hematology Associates of Northern Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inova Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Oncology &amp; Hematology Associates of Northern Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cryotherapy can effectively decrease the rate of
      neuropathy in patients undergoing weekly paclitaxel treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 2 peripheral neuropathies induced by weekly paclitaxel.</measure>
    <time_frame>From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of completion of weekly adjuvant paclitaxel with the use of cryotherapy.</measure>
    <time_frame>From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cryotherapy</intervention_name>
    <arm_group_label>Cryotherapy</arm_group_label>
    <other_name>Cold therapy</other_name>
    <other_name>Elasto gel™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Cryotherapy</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Taxanes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Women 18 years of age or older

          2. Histologically or cytological proven diagnosis of breast cancer Stage I- III.

          3. Must pl an to receive weekly paclitaxel treatment in either the adjuvant or
             neoadjuvant setting.

          4. May have received prior treatment including, radiation, surgery chemotherapy hormone
             and biologics.

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          6. Patient signed informed consent.

          7. Patient willing and able to comply with scheduled visits and treatment plan.

        Exclusion Criteria

          1. Patient presents with Grade 2 or greater peripheral neuropathy.

          2. History of Raynaud's Disease.

          3. Patient presents open or poorly-healing wounds on the hands or feet.

          4. Patients with cold intolerance.

          5. Patient has any other concurrent severe and/or uncontrolled medical condition that
             would, in the investigator's judgment contraindicate patient participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J Wilkinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology &amp; Hematology Associates of Northern Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Oncology &amp; Hematology Associates of Northern Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology &amp; Hematology Associates of Northern Virginia</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Oncology &amp; Hematology Associates of Northern Virginia</investigator_affiliation>
    <investigator_full_name>Mary Wilkinson</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Cryotherapy</keyword>
  <keyword>Cold therapy</keyword>
  <keyword>Peripheral Neuropathy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Symptom management</keyword>
  <keyword>Prevention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

